Journal Watch · Drug Discovery Today · 2026
The evolving role of China in global clinical trials: from late-stage add-on to strategic early inclusion.
On this basis, we distinguish first-wave, modular, and staged participation pathways.
TL;DR
On this basis, we distinguish first-wave, modular, and staged participation pathways.
Key findings
- On this basis, we distinguish first-wave, modular, and staged participation pathways.
What they did
In this review, we examine the main signals supporting earlier China inclusion and the conditions that determine when such inclusion is appropriate. We argue that the value of China in MRCTs depends not on speed alone, but on whether earlier participation can be translated into evidence that remains interpretable across regions, workable under governance constraints, and credible under disruption.
Full abstract (original)
Background: China is increasingly being considered for earlier inclusion in multi-regional clinical trials (MRCTs), driven by improved regulatory predictability, enhanced operational delivery, and greater outward-facing development activity. However, earlier inclusion does not guarantee that evidence will be globally interpretable, governance compatible, or resilient.
What they did: In this review, we examine the main signals supporting earlier China inclusion and the conditions that determine when such inclusion is appropriate. We argue that the value of China in MRCTs depends not on speed alone, but on whether earlier participation can be translated into evidence that remains interpretable across regions, workable under governance constraints, and credible under disruption.
Results & conclusions: On this basis, we distinguish first-wave, modular, and staged participation pathways.
Abstract © the authors / Drug Discovery Today (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.drudis.2026.104702 · PubMed 42173306.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Drug Discovery Today for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Drug Discovery Today study find?
On this basis, we distinguish first-wave, modular, and staged participation pathways.
What type of study is this?
It is a review / perspective, published in Drug Discovery Today in 2026. In this review, we examine the main signals supporting earlier China inclusion and the conditions that determine when such inclusion is appropriate.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.drudis.2026.104702. PubMed ID: 42173306. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-evolving-role-of-china-in-global-clinical-trials-from-late-stage-add-104702/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides